Increasing the symmetry of drug crystals: a monoclinic conformational polymorph of the platelet antiaggregating agent ticlopidine hydrochloride
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
19/04/2012
19/04/2012
2011
|
Resumo |
Ticlopidine hydrochloride (TICLID (R)) is a platelet antiaggregating agent whose use as a potent antithrombotic pharmaceutical ingredient is widespread, even though this drug has not been well characterized in the solid state. Only the crystal phase used for drug product manufacturing is known. Here, a new polymorph of ticlopidine hydrochloride was discovered and its structure was determined. While the antecedent polymorph crystallizes in the triclinic space group P (1) over bar, the new crystal phase was solved in the monoclinic space group P2(1)/c. Both polymorphs crystallize as racemic mixtures of enantiomeric (ticlopidine)(+) cations. Detailed geometrical and packing comparisons between the crystal structures of the two polymorphs have allowed us to understand how different supramolecular architectures are assembled. It was feasible to conclude that the main difference between the two polymorphs is a rotation of about 120 degrees on the bridging bond between the thienopyridine and o-chlorobenzyl moieties. The differential o-chlorobenzyl conformation is related to changeable patterns of weak intermolecular contacts involving this moiety, such as edge-to-face Cl center dot center dot center dot pi and C-H center dot center dot center dot pi interactions in the new polymorph and face-to-face pi center dot center dot center dot pi contacts in the triclinic crystal phase, leading to a symmetry increase in the ticlopidine hydrochloride solid state form described for the first time in this study. Other conformational features are slightly different between the two polymorphs, such as the thienopyridine puckerings and the o-chlorophenyl orientations. These conformational characteristics were also correlated to the crystal packing patterns. Brazilian Research Council CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico) CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)[AUXPE-PNPD 1865/2008] FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) FAPEMIG (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais)[APQ-02685-09] FAPEMIG (Fundacao de Amparo a Pesquisa do Estado de Minas Gerais)[APQ-01093-10] FINEP (Financiadora de Estudos e Projetos) of Brazil[134/08] |
Identificador |
CRYSTENGCOMM, v.13, n.19, p.5737-5743, 2011 1466-8033 http://producao.usp.br/handle/BDPI/16524 10.1039/c1ce05453h |
Idioma(s) |
eng |
Publicador |
ROYAL SOC CHEMISTRY |
Relação |
Crystengcomm |
Direitos |
closedAccess Copyright ROYAL SOC CHEMISTRY |
Palavras-Chave | #PRASUGREL #RECEPTOR #STROKE #Chemistry, Multidisciplinary #Crystallography |
Tipo |
article original article publishedVersion |